Altre lingue Legend Biotech Corporation

Azioni

LEGN

US52490G1022

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 23/05/2024			Variaz. 5gg	Var. 1 gen.
39,5 ^USD	-7,28%		-14,82%	-34,35%

23/05	Legend Biotech Corporation metterà in evidenza la leadership nella terapia con cellule CAR-T per i pazienti affetti da mieloma multiplo all'ASCO e all'EHA	CI
22/05	MaxCyte stringe un accordo con Legend Biotech per la fornitura di tecnologia	AN

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA	23/05
Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA	23/05
MaxCyte inks deal with Legend Biotech for tech supply	22/05
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program	22/05
Legend Expects to Log Profit in 2026	15/05
Legend Biotech's Loss Narrows in Q1 as Revenue Surges	14/05
Sector Update: Health Care Stocks Decline Pre-Bell Monday	13/05
Sector Update: Health Care	13/05
Legend Biotech Q1 Net Loss Narrows as Revenue Rises; Shares Rise Pre-Bell	13/05
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales	13/05
Stock Futures Rise Pre-Bell Ahead of Key Inflation Data; Asia, Europe Churn	13/05
Legend Biotech : LEGN Q1 2024 Earnings Presentation	13/05
Earnings Flash (LEGN) LEGEND BIOTECH CORPORATION Reports Q1 Revenue $94M	13/05
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights	13/05
Legend Biotech Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	23/04
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	22/04
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	22/04
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	22/04
US FDA mandates label updates on CAR-T cancer therapies	19/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Legend Biotech Corporation

Azioni

LEGN

US52490G1022

Altre lingue

Filtri